| Vol. 12.49 – 14 December, 2021 |
| |
|
|
| Scientists described conditionally pathogenic enhancer motif variants that differentially affected hematopoietic development and regeneration. Despite normal developmental hematopoiesis, regeneration in response to chemotherapy, inflammation, and a therapeutic HSC mobilizer was compromised. [Science Advances] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors demonstrated that lymphoid-restricted mutant IL7R, expressed at physiological levels in conditional knock-in mice, established a pre-leukemic stage in which B cell precursors displayed self-renewal ability, initiating leukemia resembling PAX5 P80R or Ph-like human B-acute lymphoblastic leukemia. [Nature Communications] |
|
|
|
| Investigators showed that inducible CD36 was required for free fatty acid uptake by HSCs during acute infection, allowing the metabolic transition from glycolysis towards β-oxidation. [Nature Communications] |
|
|
|
| Utilizing a Flt3-ITD knock-in, Dnmt3a haploinsufficient mouse model, researchers demonstrated that Gab2 was essential for the development of Flt3-ITD driven acute myeloid leukemia in vivo, as Gab2 deficient mice displayed prolonged survival. [Leukemia] |
|
|
|
| Investigators showed that in Ncx1−/− mouse embryos devoid of circulation, the HSC lineage developed until the phenotypic pro-HSC stage. Experimental activation of glycolysis resulted in decreased intraembryonic hematopoiesis. [Cell Reports] |
|
|
|
| The authors showed that cultured HSCs expressed mast cell-related genes including Cd244 and suggested CD244 was a potent marker to exclude non-functional HSCs after in vitro culture thereby useful to elucidate mechanism of functional decline of HSCs during ex vivo treatment. [iScience] |
|
|
|
| Researchers showed that in mice early-stage CD71+ erythroid cells expanded in anemia, had high levels of arginase 2 and reactive oxygen species. [Communications Biology] |
|
|
|
| The authors established inducible P18/hESC lines and monitored the effects of P18 overexpression on hematopoietic differentiation and found evidence that P18 promoted hematopoiesis, a rare property among cyclin-dependent kinase inhibitors. [Scientific Reports] |
| |
|
|
| Scientists investigated the recommended dose for expansion of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers. [Clinical Cancer Research] |
|
|
|
| Investigators evaluated the effect of HU on immune profiles through a controlled prospective cohort study conducted in 30 children with sickle cell anemia and 30 healthy age-matched controls. [Pediatric Research] |
| |
|
|
|
| The authors provide a clinical decision support tool for pediatric hematologists, oncologists, and critical care physicians during the difficult decision-making process of extracorporeal membrane oxygenation candidacy and management. [Lancet Child & Adolescent Health] |
|
|
|
| Scientists review relevant literature, considering endpoints of both survival and long term quality of life and retrospectively evaluate patients with metastatic germ cell tumor progressing after first-line treatment. [Critical Reviews in Oncology Hematology] |
|
|
|
|
| Mustang Bio, Inc. announced updated data from the ongoing Phase I/II clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. [Mustang Bio, Inc.] |
|
|
|
|
| January 23 – 26, 2022 Santa Fe, New Mexico, United States |
|
|
|
|
|
| Memorial Sloan Kettering – New York City, New York, United States |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|